Karl Kieburtz, MD, MPH, is the T1 Translation Key Function Director and the Director of the Center for Human Experimental Therapeutics (CHET) at the URMC. He is the Robert J. Joynt Professor in Neurology and Professor of Community and Preventive Medicine and Environmental Medicine. CHET conducts learning phase clinical trials in a wide spectrum of disorders in collaboration with investigators within the University of Rochester Medical Center (URMC) as well as with colleagues throughout North America, Europe, Asia and Oceania. Dr Kieburtz's primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and directs the Coordination Center for an NEI-funded consortium in Neuro-opthalmology.
He completed his MD and MPH degrees at the University of Rochester, as well as his Neurology residency and a fellowship in Experimental Therapeutics.